06 Dec

Aptorum Group Limited Announces Pricing of Initial Public Offering


Aptorum Group Limited (“Aptorum”, or the “Company”), a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced that on December 3, 2018, its registration statement on Form F-1, relating to a proposed initial public offering (“IPO” or the “Offering”) of its Class A Ordinary Shares, par value US$1.00 per share (the “Shares”), at a price to the public of $15.80 per share, for gross proceeds of a minimum of US$10 million and up to US$30 million, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). The Company is offering up to 1,898,734 Shares and up to 51,990 underwriter warrants while certain selling shareholders are offering up to 1,595,235 Shares (collectively, the “Registered Securities”). None of the gross proceeds will be used to purchase the selling shareholders’ securities. The Shares are expected to begin trading on The NASDAQ Global Market on December 18, 2018, under the symbol APM. This Offering is expected to close on or before December 12, 2018, subject to customary closing conditions.

The Offering will be sold on a best-efforts basis. Boustead Securities, LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets Limited are acting as Co-Underwriters for the Offering.

As stated above, a registration statement relating to the Registered Securities (File No.: 333-227198) has been filed with the SEC and was declared effective on December 3, 2018. The Offering is made only by means of a written prospectus forming part of the effective registration statement. A copy of the prospectus may be obtained for free by visiting EDGAR on the SEC's website at Alternatively, copies of the prospectus relating to this Offering may be obtained from: Boustead Securities, LLC, email: or by calling +1 (949) 502-4409 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aptorum Group Limited

We are a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. We have obtained exclusive licenses for our technologies. In addition, we are also developing certain proprietary technologies as product candidates. We are pursuing therapeutic and diagnostic projects (including projects seeking to use extracts or derivatives from natural substances to treat diseases) in neurology, infectious diseases, gastroenterology, oncology and other disease areas. We also have projects focused on surgical robotics. In addition, we opened a medical clinic, AML Clinic, in June 2018. Its initial focus is on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population. For more information about the Company, please visit

About Boustead Securities, LLC

Boustead Securities, LLC ("Boustead") is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead's core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit

About China Renaissance Securities (Hong Kong) Limited

China Renaissance (“CR”) is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new economy entrepreneurs and investors globally. CR has offices in Beijing, Shanghai, Hong Kong and New York, with approximately 600 employees. As of March 31, 2018, CR had advised on approximately 700 transactions worth over US$100 billion since the inception, and CR had AUM of approximately US$4.1 billion in new economy investments. For more information, visit

About AMTD Global Markets Limited

AMTD Global Markets Limited (“AMTD”) is a Hong Kong-based comprehensive financial institution dedicated to serving and bridging capital and resources across mainland China, Hong Kong and the globe. As one of the largest Hong Kong-based non-bank financial institution, AMTD has been widely recognized as a pre-eminent capital markets player with leading cross-border investment banking capabilities in Asia. Founded in 2003, AMTD has a long history of promoting technological innovations and the development of New Economy sectors, especially in the fields of FinTech, Artificial Intelligence and Healthcare. For more information, visit

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding listing on the NASDAQ Global Market and the completion of the IPO are forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, risks and uncertainties related to the satisfaction of the customary closing conditions related to the IPO and the listing on NASDAQ . For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof unless required by the applicable laws, regulations or rules.

For more information, please contact:
At the Company:
Sabrina Khan, CFO
Aptorum Group Limited
Phone: +852 2117 6611


07 Nov
20 Oct

The First Influenza Drug against Nucleoprotein is About to Enter the Clinical Stage

(Chinese version only)

<Shenzhen Evening News>

對抗流感、子宮內膜異位癥和超級細菌未來將或有新的辦法。10 月 18 日,在知臨集團主辦的香港醫療保健與經濟氣候研討會上,知臨集團發布了當前三個先導項目,包括診斷或者治療流感(ASL-1)、耐甲氧西林金黃色葡萄球菌(ALS-4)、子宮內膜異位癥(NSL-1)。這三個先導項目即將進入臨床階段。

據了解,我國作為癌癥高發區,醫療市場規模逐年遞增,現已成為全球增速最快的生物科技市場。生物醫療科技行業作為一個高風險,高回報的行業,也受到政府的重點關註和大力支持。與此同時,香港作為生物科技投資中心,坐擁近 300 家生物科技相關公司,無論是科研環境或是人才資源都堪稱世界一流。香港科技園已經為新興生物醫療科技公司建立了生物醫療科技支援中心和醫療保健設備研發中心,同時也提供了大量的先進設備支持以助力新興生物醫療科技公司的發展。

據知臨集團創辦人、行政總裁兼執行董事禤駿遠介紹,知臨集團當前三個先導項目包括:診斷或者治療流感(ASL-1)、耐甲氧西林金黃色葡萄球菌(ALS-4)、子宮內膜異位癥(NSL-1)。其中 ASL-1 是一種用於治療甲型流感病毒引起的病毒性感染的小分子藥物,是首創針對核蛋白的新型抗流感候選藥物,與所有目前市場上存在耐藥性問題的抗甲型流感病毒藥物區別開來;而 ALS-4 首創 " 免疫療法 ",通過加強免疫系統對金黃葡萄球菌 ( MRSA ) 的清除功能,防止 MRSA 避過人體免疫系統的防禦侵害人體,是該領域的一項極具突破性的發現。集團的第三個重點項目 NSL-1 是一種用於治療子宮內膜異位癥衍生物。該藥物相比於其他藥物的成效更高、更能夠完全消除子宮內膜異位癥病變。集團的三個先導項目當前均即將進入臨床階段,市場規模有望在 2025 年累計突破 70 億美元。



Terms of Use

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.